Estrella Immunopharma Inc Dossier
Qualitative Analysis
Business overview
Estrella Immunopharma, Inc. (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing next-generation T-cell therapies to treat cancer and autoimmune diseases. The company's proprietary ARTEMIS® T-cell engineering platform is designed to provide more controlled signaling within CAR-T cells, enhancing T-cell persistence, tumor specificity, and overall safety while reducing severe toxicities like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Its lead clinical candidate is EB103, a CD19-directed ARTEMIS T-cell therapy currently in Phase I/II clinical trials (STARLIGHT-1) for relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). The pipeline also includes EB104, a dual-target CD19/CD22 candidate, and preclinical programs targeting autoimmune diseases and solid tumors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the Phase II clinical trial of EB103, a CD19-targeting ARTEMIS T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL).
Expected impact: Aims to establish the recommended Phase II dose (RP2D) and gather robust safety and efficacy data to support potential pivotal trial strategies.
Evaluating the combination of Imugene's CF33-CD19t oncolytic virus technology with Estrella's EB103 CD19 ARTEMIS T-cell therapy to treat solid tumors.
Expected impact: Forces solid tumor cells to express CD19, allowing EB103 T-cells to target and destroy them, potentially overcoming the lack of tumor-specific targets in solid cancers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Estrella with the exclusive license to develop CD19 and CD22-targeted T-cell therapies using Eureka's proprietary ARTEMIS platform [1.2.3]. Eureka also provides essential clinical trial execution and manufacturing services.
Terms: Estrella pays development and sales milestones, plus single-digit percentage royalties on net sales. Under the STARLIGHT-1 SOW, Estrella committed up to $33.5 million in milestone-based fees.
Collaborative evaluation of Imugene's CF33-CD19t oncolytic virus in combination with Estrella's EB103 to enable a 'mark and kill' therapeutic approach for solid tumors.
Terms: Collaborative research terms; specific financial figures for the joint development are not publicly disclosed.